StoxAster DM Quality Care vs Biocon: share price & financials comparison
NSE: ASTERDM vs BIOCON · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Aster DM Quality Care vs Biocon at a glance
Aster DM Quality Care (ASTERDM) has a market capitalisation of ₹62,979 Cr, against ₹59,326 Cr for Biocon (BIOCON). Over the past year Aster DM Quality Care has returned +4.9%, compared with -4.3% for Biocon. On valuation, Biocon trades at a lower P/E of 131.2 versus 133.8. Aster DM Quality Care earns a higher return on equity (6.0% vs 1.3%). Aster DM Quality Care comes out ahead on size, profitability, growth, momentum and technicals. Biocon comes out ahead on valuation and financial health. Across the scored metrics below, Aster DM Quality Care leads on 12 and Biocon on 5. On StoxGud's 10-point checklist, Aster DM Quality Care scores 5/10 and Biocon scores 2/10.
| Metric | Aster DM Quality Care | Biocon |
|---|---|---|
| Size | ||
| Market cap | ₹62,979 Cr | ₹59,326 Cr |
| Revenue (latest FY) | ₹4,643 Cr | ₹16,927 Cr |
| Net profit (latest FY) | ₹388 Cr | ₹386 Cr |
| Valuation | ||
| P/E | 133.8 | 131.2 |
| P/B | 8.08 | 1.70 |
| Dividend yield | 0.09% | 0.15% |
| Profitability | ||
| Return on equity | 6.0% | 1.3% |
| Net profit margin | 7.2% | 2.6% |
| Operating margin | 21.1% | 20.3% |
| Growth | ||
| Revenue growth (YoY) | +136.3% | +2.2% |
| Net profit growth (YoY) | +138.2% | -51.1% |
| Revenue CAGR (multi-year) | -11.6% | +19.0% |
| Financial health | ||
| Debt to equity | 0.51 | 0.43 |
| Momentum | ||
| 1-month return | +4.7% | +3.7% |
| 1-year return | +4.9% | -4.3% |
| 3-year CAGR | +28.3% | +17.0% |
| 5-year CAGR | +28.4% | +0.1% |
| 10-year CAGR | — | +9.8% |
| Distance from 52W high | -16.9% | -17.4% |
| Technicals | ||
| RSI (14) | 76 | 76 |
| Price vs 200-day avg | +0.5% | -6.7% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Aster DM Quality Care | Biocon |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 5/10 | 2/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Aster DM Quality Care or Biocon?
Aster DM Quality Care has a market cap of ₹62,979 Cr and Biocon has a market cap of ₹59,326 Cr as of 13 Nov 2026.
Which has a lower P/E, Aster DM Quality Care or Biocon?
Biocon has the lower P/E: Aster DM Quality Care trades at 133.8 and Biocon at 131.2.
Which gave better returns in the last year, Aster DM Quality Care or Biocon?
Aster DM Quality Care did better: Aster DM Quality Care returned +4.9% and Biocon returned -4.3% over one year.
What is the difference between Aster DM Quality Care and Biocon?
Both are NSE-listed companies in Healthcare. They are about the same size by market cap (₹62,979 Cr vs ₹59,326 Cr). In the latest financial year Aster DM Quality Care reported revenue of ₹4,643 Cr and Biocon ₹16,927 Cr. Operating margin is 21.1% for Aster DM Quality Care and 20.3% for Biocon. Debt to equity is 0.51 for Aster DM Quality Care and 0.43 for Biocon.
Which is better, Aster DM Quality Care or Biocon?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Aster DM Quality Care leads on 12 and Biocon on 5. Aster DM Quality Care is ahead on size, profitability, growth, momentum and technicals. Biocon is ahead on valuation and financial health. On StoxGud's rules-based checklist Aster DM Quality Care scores 5/10 and Biocon scores 2/10. This is information, not advice: consult a SEBI-registered adviser before investing.